Event Details Study Design and Participant Characteristics of a Phase 2 Trial of Fosgonimeton, a Novel Treatment for Mild to Moderate Alzheimer’s Disease March 20, 2022 Supporting Materials View Presentation 774.4 KB < SIGN UP FOR EMAIL ALERTS CONTACT IR
Study Design and Participant Characteristics of a Phase 2 Trial of Fosgonimeton, a Novel Treatment for Mild to Moderate Alzheimer’s Disease March 20, 2022 Supporting Materials View Presentation 774.4 KB
